DMAC (DiaMedica Therapeutics) Insider Ownership: 3.05 % (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $7.64
! 2 Warning Signs
View Full Analysis

What is DiaMedica Therapeutics Insider Ownership?

DiaMedica Therapeutics DMAC +2.76% 31 Insider Ownership is 3.05 % as of Jul. 16, 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, DiaMedica Therapeutics's insider ownership is 3.05%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, DiaMedica Therapeutics's Institutional Ownership is 23.17%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, DiaMedica Therapeutics's Float Percentage Of Total Shares Outstanding is 67.10%.

DiaMedica Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Insider Ownership Chart

DiaMedica Therapeutics Historical Data

The historical data trend for DiaMedica Therapeutics can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 3.76 3.76 3.76 3.76 3.76 3.79 3.83 3.83 3.05 3.05
DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 3.05 % mean?
DiaMedica Therapeutics (DMAC) has a Insider Ownership of 3.05 % as of Jul. 16, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' Insider Ownership too high?
DiaMedica Therapeutics' current Insider Ownership is 3.05 %. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Insider Ownership compare to PRLD and RCKT?
DiaMedica Therapeutics' Insider Ownership of 3.05 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Insider Ownership is 3.05 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Insider Ownership of 3.05 %. The current Insider Ownership is 3.05 %. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Insider Ownership is 3.05 % as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.64
Price